Colleen Kusy
Stock Analyst at Baird
(1.67)
# 3,455
Out of 5,113 analysts
50
Total ratings
42.22%
Success rate
-3.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Downgrades: Neutral | $924 → $858 | $814.74 | +5.31% | 1 | Dec 18, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $112 → $158 | $106.44 | +48.44% | 3 | Nov 18, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $14 → $34 | $36.68 | -7.31% | 1 | Nov 11, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $50 → $52 | $21.75 | +139.08% | 13 | Oct 31, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $17 → $24 | $10.27 | +133.69% | 5 | Oct 3, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | $9 | $5.02 | +79.28% | 1 | Aug 15, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $25.78 | +101.71% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $3.24 | +85.19% | 4 | Jun 4, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $27.15 | +51.01% | 4 | Mar 13, 2025 | |
| CHRS Coherus Oncology | Maintains: Outperform | $4 → $6 | $2.06 | +191.26% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $65 | $32.04 | +102.90% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 → $25 | $11.99 | +108.51% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $6.59 | +3,086.65% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $2.64 | +1,187.88% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $4.04 | +5,593.07% | 1 | Nov 2, 2021 |
argenx SE
Dec 18, 2025
Downgrades: Neutral
Price Target: $924 → $858
Current: $814.74
Upside: +5.31%
Nuvalent
Nov 18, 2025
Maintains: Outperform
Price Target: $112 → $158
Current: $106.44
Upside: +48.44%
Cogent Biosciences
Nov 11, 2025
Maintains: Neutral
Price Target: $14 → $34
Current: $36.68
Upside: -7.31%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Outperform
Price Target: $50 → $52
Current: $21.75
Upside: +139.08%
Ocular Therapeutix
Oct 3, 2025
Maintains: Outperform
Price Target: $17 → $24
Current: $10.27
Upside: +133.69%
Climb Bio
Aug 15, 2025
Initiates: Outperform
Price Target: $9
Current: $5.02
Upside: +79.28%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $25.78
Upside: +101.71%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $3.24
Upside: +85.19%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $27.15
Upside: +51.01%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $2.06
Upside: +191.26%
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $32.04
Upside: +102.90%
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $11.99
Upside: +108.51%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $6.59
Upside: +3,086.65%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $2.64
Upside: +1,187.88%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $4.04
Upside: +5,593.07%